Vertex Pharmaceuticals (MEX:VRTX) Cyclically Adjusted Book per Share: MXN744.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VRTX Vertex Pharmaceuticals Inc MEX:VRTX
91 GF Score
Price MXN8,474.00
GF Value MXN8,914.24
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cyclically Adjusted Book per Share?

Vertex Pharmaceuticals MEX:VRTX -0.66% 91 Cyclically Adjusted Book per Share is MXN744.21 as of Mar. 2026. GuruFocus rates MEX:VRTX with a GF Score™ of 91/100 and a GF Value™ of MXN8,914.24 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was MXN1,373.709. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN744.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 23.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 26.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 31.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 29.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Vertex Pharmaceuticals was 38.60% per year. The lowest was -7.70% per year. And the median was 7.15% per year.

As of today (2026-07-14), Vertex Pharmaceuticals's current stock price is MXN8474.00. Vertex Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN744.21. Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 11.39.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 10.21. And the median was 17.86.


Vertex Pharmaceuticals  (MEX:VRTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=8474.00/744.21
=11.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Vertex Pharmaceuticals was 39.61. The lowest was 10.21. And the median was 17.86.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Vertex Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 293.18 371.60 427.93 660.32 709.64

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 701.45 666.13 667.00 709.64 744.21

MEX:VRTX vs REGN, ALNY, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:VRTX
91GF Score
Vertex Pharmaceuticals Inc MEX:VRTX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1373.709/330.2130*330.2130
=1,373.709

Current CPI (Mar. 2026) = 330.2130.

Vertex Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 73.268 241.018 100.383
201609 79.636 241.428 108.922
201612 96.034 241.432 131.348
201703 113.478 243.801 153.699
201706 120.469 244.955 162.399
201709 128.637 246.819 172.100
201712 157.314 246.524 210.718
201803 171.153 249.554 226.472
201806 207.087 251.989 271.372
201809 212.663 252.439 278.182
201812 341.280 251.233 448.568
201903 357.412 254.202 464.285
201906 379.429 256.143 489.150
201909 403.135 256.759 518.464
201912 443.131 256.974 569.426
202003 584.813 258.115 748.166
202006 667.220 257.797 854.644
202009 690.601 260.280 876.154
202012 664.888 260.474 842.904
202103 709.215 264.877 884.154
202106 706.498 271.696 858.661
202109 764.894 274.310 920.776
202112 814.179 278.802 964.313
202203 849.728 287.504 975.956
202206 937.710 296.311 1,044.997
202209 1,021.214 296.808 1,136.149
202212 1,055.367 296.797 1,174.189
202303 1,010.222 301.836 1,105.198
202306 1,028.808 305.109 1,113.457
202309 1,115.603 307.789 1,196.880
202312 1,158.013 306.746 1,246.605
202403 1,191.672 312.332 1,259.895
202406 1,049.063 314.175 1,102.616
202409 1,194.138 315.301 1,250.614
202412 1,331.960 315.605 1,393.611
202503 1,313.333 319.799 1,356.101
202506 1,261.833 322.561 1,291.767
202509 1,251.027 324.800 1,271.876
202512 1,323.239 324.054 1,348.389
202603 1,373.709 330.213 1,373.709

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN744.21 mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Cyclically Adjusted Book per Share of MXN744.21 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Vertex Pharmaceuticals' current Cyclically Adjusted Book per Share is MXN744.21. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cyclically Adjusted Book per Share compare to REGN and ALNY?
Vertex Pharmaceuticals' Cyclically Adjusted Book per Share of MXN744.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cyclically Adjusted Book per Share is MXN744.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,914.24, compared to a current price of MXN8,474.00 — trading 4.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN744.21. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Cyclically Adjusted Book per Share is MXN744.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of MXN8,474.00 is trading 4.9% below its estimated GF Value™ of MXN8,914.24. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:VRTX:

  • Cyclically Adjusted Book per Share: MXN744.21
  • GF Value™: MXN8,914.24 vs. price of MXN8,474.00 (4.9% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score

Get the complete analysis for MEX:VRTX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN8,474.00
Price
MXN8,914.24
GF Value